| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BeiGene, AbbVie patent spat to get trial from USPTO appeals board | 6 | Seeking Alpha | ||
| Mo | BEIGENE (06160): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| Mo | BEIGENE (06160): FORM OF PROXY | 1 | HKEx | ||
| Mo | BEIGENE (06160): NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS | 1 | HKEx | ||
| Mo | BEIGENE (06160): 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROXY STATEMENT/ CIRCULAR | 1 | HKEx | ||
| Fr | BeiGene, Ltd.: BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report | 216 | Business Wire | Newly released report details Company's achievements and plans for sustainable growth
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible... ► Artikel lesen | |
| Fr | BeiGene's Tizveni receives EC approval to treat non-small cell lung cancer | 2 | PMLiVE | ||
| 25.04. | BeiGene, Ltd.: Globaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide Tumore | 114 | Business Wire | Mehrere Präsentationen zur Vorstellung der Wirksamkeit und Sicherheit von BRUKINSA bei einer Reihe von B-Zell-Malignomen Unternehmen präsentiert Dreijahresdaten der RATIONALE-306-Studie zu TEVIMBRA... ► Artikel lesen | |
| 25.04. | BEIGENE (06160): 2023 RESPONSIBLE BUSINESS AND SUSTAINABILITY REPORT | 1 | HKEx | ||
| 25.04. | BEIGENE (06160): 2023 ANNUAL REPORT | 1 | HKEx | ||
| 24.04. | BeiGene, Ltd.: Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting | 206 | Business Wire | Multiple presentations to showcase the efficacy and safety of BRUKINSA across a range of B-cell malignancies Company to present three-year data from RATIONALE-306 study of TEVIMBRA in advanced... ► Artikel lesen | |
| 24.04. | Evaluating BeiGene: Insights From 6 Financial Analysts | 4 | Benzinga.com | ||
| 24.04. | EU OK sets up first ex-China launches for BeiGene's Tevimbra | 2 | pharmaphorum | ||
| 24.04. | BeiGene, Ltd.: BeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem Lungenkrebs | 313 | Business Wire | Umfassendes Entwicklungsprogramm mit drei klinischen Phase-3-Studien zeigt den Nutzen von Tislelizumab bei Patienten mit nicht vorbehandeltem, rezidivierendem NSCLC Entscheidung der EU-Kommission... ► Artikel lesen | |
| 23.04. | BeiGene, Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.04. | EC approves BeiGene's tislelizumab for three NSCLC indications | 1 | Pharmaceutical Technology | ||
| 23.04. | EU regulators approve BeiGene's tislelizumab for lung cancer | 2 | Seeking Alpha | ||
| 23.04. | BeiGene's Tislelizumab Granted EC Approval For Non-Small Cell Lung Cancer Treatment | 2 | RTTNews | ||
| 23.04. | BEIGENE (06160): VOLUNTARY ANNOUNCEMENT - UPDATE REGARDING RECENT BUSINESS DEVELOPMENTS | 1 | HKEx | ||
| 23.04. | BeiGene, Ltd.: BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer | 215 | Business Wire | Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab for patients with treatment-naïve and relapsed NSCLC Decision represents tislelizumab's... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 2.981 |
| SUPER MICRO COMPUTER | 2.256 |
| BAYER | 1.751 |
| BYD | 1.541 |
| NVIDIA | 1.410 |
| AMAZON | 1.339 |
| DEUTSCHE BANK | 1.223 |
| NEL | 1.176 |
| TUI | 1.157 |
| TESLA | 1.154 |
| PFIZER | 939 |
| MERCEDES-BENZ | 856 |
| CANOPY GROWTH | 777 |
| AMD | 761 |
| VOLKSWAGEN | 727 |
| PAYPAL | 722 |
| COMMERZBANK | 719 |
| STARBUCKS | 691 |
| PLUG POWER | 654 |
| NOVO NORDISK | 642 |
| AIXTRON SE | 636 |
| BARRICK GOLD | 602 |
| RHEINMETALL | 557 |
| DEUTSCHE LUFTHANSA | 542 |
| HUGO BOSS | 539 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
